News

The company has completed the submission of a new drug application (NDA) to the regulator for fostemsavir. Fostemsavir, an investigational prodrug of temsavir, is a first-in-class HIV-1 attachment

Gatehouse Bio’s ‘sRNAlytics platform’ identifies novel small RNA (sRNA) signatures and illuminates molecular pathways correlated to and potentially driving disease. “Our annotation library of over 1.4M small RNA

This enterprise-wide data and analytics platform is expected to form the foundation for custom solutions powered by AWS AI and ML services to help drive agility, innovation, and

GvHD is a potentially life-threatening medical complication, which can affect patients receiving such transplants to treat certain genetic diseases and haematologic cancers. Orencia is an immunomodulator that disturbs

The transaction has been taken up by AstraZeneca as the compound patent protection of the two drugs is no longer valid in the two countries. It would also

Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review

The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties. IONTAS’

The approval has been granted for Tecentriq in combination with Abraxane (paclitaxel protein-bound; nab-paclitaxel) and carboplatin for the first-line treatment of adults with metastatic NSCLC with no EGFR

As part of the deal, STADA will also acquire Biopharma’s two GMP-certified production facilities in the city of Bila Tserkva, Kiev. The shareholders of Biopharma will retain the